The stock of Cabaletta Bio Inc (CABA) has gone up by 17.59% for the week, with a -23.49% drop in the past month and a -50.97% drop in the past quarter. The volatility ratio for the week is 9.57%, and the volatility levels for the past 30 days are 11.95% for CABA. The simple moving average for the past 20 days is 4.03% for CABA’s stock, with a -63.99% simple moving average for the past 200 days.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
Moreover, the 36-month beta value for CABA is 2.68. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CABA is 46.16M and currently, short sellers hold a 13.27% of that float. On April 25, 2025, CABA’s average trading volume was 1.07M shares.
CABA) stock’s latest price update
Cabaletta Bio Inc (NASDAQ: CABA) has experienced a decline in its stock price by -5.22 compared to its previous closing price of 1.34. However, the company has seen a gain of 17.59% in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “We are looking forward to meeting with the FDA to align on registrational trial designs in myositis, which affects approximately 70,000 patients in the U.S., by leveraging our emerging clinical data and our efficient development strategy.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Evercore ISI repeating the rating for CABA by listing it as a “In-line.” The predicted price for CABA in the upcoming period, according to Evercore ISI is $6 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see CABA reach a price target of $6, previously predicting the price at $12. The rating they have provided for CABA stocks is “Equal Weight” according to the report published on December 19th, 2024.
UBS gave a rating of “Buy” to CABA, setting the target price at $10 in the report published on October 10th of the previous year.
CABA Trading at -22.69% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.71% of loss for the given period.
Volatility was left at 11.95%, however, over the last 30 days, the volatility rate increased by 9.57%, as shares sank -19.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.30% lower at present.
During the last 5 trading sessions, CABA rose by +17.59%, which changed the moving average for the period of 200-days by -83.20% in comparison to the 20-day moving average, which settled at $1.2205. In addition, Cabaletta Bio Inc saw -44.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CABA
The total capital return value is set at -0.79. Equity return is now at value -59.64, with -52.35 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.66. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -167.3.
Currently, EBITDA for the company is -125.14 million with net debt to EBITDA at 1.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.15.
Conclusion
To wrap up, the performance of Cabaletta Bio Inc (CABA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
